Introduction: Aedes-borne arboviral infections, both imported and autochthonous, are reported in Europe. We evaluated the landscape of these infections in Europe over 23 years and attempted to pre-empt the trajectory of impact of these infections in the climatic context of Aedes mosquito expansion in Europe.
Methods: This systematic review was conducted in accordance with PRISMA guidelines and registered in Prospero (CRD42023360259). PubMed, Embase, Web of Science, IEEE Xplore, and Cochrane Central Register of Controlled Trials (CENTRAL) databases and the European Centre for Disease Prevention and Control (ECDC) websites were searched for publications reporting on cases of Aedes-borne infection in Europe between January 1st, 2000, and December 31st, 2023.
Results: Some 353 papers were included, covering 59,589 cases of infection in Europe by seven arboviruses: dengue, Zika, chikungunya, yellow fever, Mayaro, Ross River, and Rift Valley. Most cases (55,924) were travel related, while 5 % were autochthonous. There were 59 cases of non-vector-borne transmission, primarily Zika-related sexual transmissions. Nineteen deaths were reported, of which three were associated with chikungunya virus infection, 12 with dengue, and four with yellow fever. Notable sequelae included persistent arthralgia from chikungunya and neurological effects in Zika-infected infants. The meta-analysis of 31 studies revealed a pooled prevalence of 0.047 (95 % CI: 0.03-0.07) in symptomatic returning travelers.
Conclusion: The systematic review provides a comprehensive overview of over 20 years of Aedes -borne infections in Europe, highlighting the dynamic nature of virus transmission influenced by global travel patterns, climate change, the expanding spread of Aedes populations, and evolving public health campaigns.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.tmaid.2025.102799 | DOI Listing |
J Viral Hepat
February 2025
Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
This study aimed to evaluate the effectiveness of direct-acting antivirals (DAAs) on hepatitis C virus (HCV) hospitalisation trends in Italy, the country with not only the highest burden of HCV-related disease but also the highest number of patients treated for chronic HCV infection in Europe. Incident hospital discharge records in Italy from 2012 to 2019 that included a liver cirrhosis diagnosis without mention of alcohol, hepatocellular carcinoma (HCC), HCV and liver cirrhosis without mention of alcohol and/or HCC, cirrhosis with mention of alcohol, as defined by the International Classification of Diseases (ICD-9-CM) were reviewed. An interrupted time series analysis compared the incidence of cirrhosis and HCC before and after the introduction of DAAs (Year 2015).
View Article and Find Full Text PDFClin Kidney J
January 2025
Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Oxford Road, Manchester, UK.
Background And Hypothesis: Mild cognitive impairment and dementia (CI) are common in patients with CKD. We aim to clarify whether and how CKD and CI coexistence increases adverse health outcomes.
Methods: This retrospective observational cohort study was conducted on CKD patients (stages 3-5) from the TriNetX platform.
J Med Virol
February 2025
Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
The determinants of varicella-zoster virus (VZV)-associated central nervous system (CNS) infection have not been fully elucidated. This study aimed to investigate the incidence and risk factors, including immunosuppression, for different manifestations of VZV-associated CNS infection. Patient registers were used to include adults diagnosed with VZV-associated CNS infections between 2010 and 2019 in Sweden.
View Article and Find Full Text PDFBMC Cancer
January 2025
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: Even though major improvements have been made in the treatment of myeloma, the majority of patients eventually relapse or progress. Patients with multiple myeloma who relapse after initial high-dose chemotherapy with autologous stem cells have a median progression free survival up to 2-3 years, depending on risk factors such as previous remission duration. In recent years, growing evidence has suggested that allogeneic stem cell transplantation could be a promising treatment option for patients with relapsed or progressed multiple myeloma.
View Article and Find Full Text PDFAIDS Behav
January 2025
Division of Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, G7, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
People with HIV (PWH) are at greater risk of experiencing mental health problems, such as depression and post-traumatic stress disorder (PTSD). The purpose of our study was to determine the prevalence of posttraumatic stress disorder PTSD in PWH. PWH in care Amsterdam University Medical center (Amsterdam UMC) with access to the electronic patient portal were offered patient-reported outcome measures (PROMs) between May 2022 and May 2023, including the PC-PTSD-5 screen for PTSD as part of routine clinical care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!